



Benzyne-mediated rearrangement of 3-(2-pyridyl)-1,2,4-triazines into 10-(1*H*-1,2,3-triazol-1-yl)pyrido[1,2-*a*]indoles



Igor L. Nikonov ^a, Dmitry S. Kopchuk ^{a,b}, Igor S. Kovalev ^a, Grigory V. Zyryanov ^{a,b,*}, Albert F. Khasanov ^a, Pavel A. Slepukhin ^b, Vladimir L. Rusinov ^{a,b}, Oleg N. Chupakhin ^{a,b}

^a Ural Federal University, 19, Mira St., 620002 Ekaterinburg, Russia

^b Postovsky Institute of Organic Synthesis of RAS (Ural Branch), 22/20, S. Kovalevskoy/Akademicheskaya St., 620990 Ekaterinburg, Russia

ARTICLE INFO

Article history:

Received 10 July 2013

Revised 22 August 2013

Accepted 12 September 2013

Available online 20 September 2013

ABSTRACT

The reaction between 5-R-6-R¹-3-(2-pyridyl)-1,2,4-triazines and benzyne generated *in situ* in toluene under reflux results in the formation of 10-(1*H*-1,2,3-triazol-1-yl)pyrido[1,2-*a*]indoles **3** in up to 60% yields instead of the expected 3-R-4-R¹-1-(2-pyridyl)isoquinolines **2**. The crystal structure of product **3c** and the proposed mechanism for the formation of **3** are reported.

© 2013 Elsevier Ltd. All rights reserved.

Keywords:

Arynes

1,2,4-Triazines

Rearrangement

1,2,3-Triazoles

Pyrido[1,2-*a*]indoles

Aryne intermediates are of wide use as versatile tools for the synthesis of various heteroaromatic systems,¹ including photoluminescent intercalators² and other physiologically active compounds, such as alkaloids and their carbo- and heterocyclic analogs,³ and fluorescent sensors for nitroaromatics.⁴ At present, most of these compounds can be obtained via the one-step Diels–Alder reaction between various heteroaromatic dienes and cyclic (het)arynes as dienophiles. However, little attention has been given to the reactions of arynes as dienophiles and various cyclic azines as extremely active dienes, the so-called inverse electron demand Diels–Alder reactions.⁵ In particular, only a few cases of reactions between 1,2,4-triazines and benzyne to afford isoquinolines in low yields have been described.⁶ Moreover, only two cases have been reported for the formation of benzene-annelated analogs of highly promising 2,2'-bipyridine-type ligands⁷ by the one-step inverse electron demand Diels–Alder reaction between 5-phenyl-3-(2-pyridyl)-1,2,4-triazine and *in situ* generated benzyne under very harsh conditions: autoclave, toluene, 140 °C,⁸ or by heating in *o*-dichlorobenzene at 160 °C.⁹

In addition, we have developed an alternative synthetic approach toward aryl-substituted 1-(2-pyridyl)isoquinolines via the Diels–Alder reaction of 3-(2-pyridyl)-1,2,4-triazines with

1-morpholinocyclohexene followed by aromatization of the resultant tetrahydrosouquinolines.¹⁰

Herein we report the results of our study on the reactions of het(aryl)-substituted-1,2,4-triazines with benzyne, which was aimed at the development of a convenient method for the one-pot conversion of 1,2,4-triazines into isoquinolines, including benzene-annelated 2,2'-bipyridyl ligands.


Aryl-substituted 3-(2-pyridyl)-1,2,4-triazines **1a–c** were synthesized according to published methods¹¹ and were used as the starting materials (**Scheme 1**).

Surprisingly, in the reactions between **1a–c** and benzyne generated *in situ* from 2-aminobenzoic acid and isoamyl nitrite¹² in toluene under reflux, we did not observe the formation of the expected pyridyl-isoquinolines **2**.

Analysis of the ¹H NMR spectra of the obtained products and compound **2a**, prepared by an alternative method,¹⁰ did not show any matches, that is, the resonances of the aromatic protons in the products were downfield compared to the similar resonances observed for compound **2a**. In addition, according to ESI-mass spectrometry there were four nitrogen atoms in molecules of products **3a–c** versus two nitrogen atoms in product **2a**. The initial suggestion that the reaction of compound **1** and benzyne afforded only the 3,6-cycloaddition products without elimination of a nitrogen molecule was ruled out by the results of ¹³C NMR measurements: there were no signals due to sp³-hybridized carbons in the ¹³C NMR spectra for products **3a–c**. In order to confirm the structures

* Corresponding author. Tel.: +7 343 375 4501; fax: +7 343 374 0458.

E-mail address: gvzyryanov@gmail.com (G.V. Zyryanov).



Scheme 1. Benzene-mediated transformation of 3-(2-pyridyl)-1,2,4-triazines into 10-(1*H*-1,2,3-triazol-1-yl)pyrido[1,2-*a*]indoles. Reagents and conditions: (i) toluene, isoamyl nitrite, 110 °C, 1.5 h.





Figure 1. ORTEP view of the crystal structure of **3c**. Displacement parameters at 50% of the electron density. Selected bond distances (Å) and angles (°): N(1)–C(14) 1.359(2), N(1)–N(2) 1.371(2), N(1)–C(20) 1.409(2), C(1)–N(3) 1.355(2), N(2)–N(3) 1.306(2), N(4)–C(26) 1.385(2), N(4)–C(15) 1.401(2), N(4)–C(19) 1.400(2), C(21)–C(26) 1.387(2), C(25)–C(26) 1.361(3), N(3)–N(2)–N(1) 107.61(15), N(2)–N(3)–C(1) 108.92(16), C(14)–N(1)–N(2) 109.54(16), C(14)–N(1)–C(20) 132.42(17), C(26)–N(4)–C(15) 130.2(2), C(26)–N(4)–C(19) 108.20(18), C(15)–N(4)–C(19) 121.5(2), C(25)–C(26)–N(4) 128.7(2), C(25)–C(26)–C(21) 123.1(2), N(4)–C(26)–C(21) 108.23(18).


of products **3a–c**, we performed X-ray crystal analysis of a single crystal of compound **3c** (Fig. 1). The X-ray diffraction data obtained revealed the structure of product **3c** as 10-(1*H*-1,2,3-triazol-1-yl)pyrido[1,2-*a*]indole.¹³

Based on the structures of products **3a–c** a plausible mechanism can be suggested (Scheme 2). Thus, the initial step involves the concerted or step-wise [2+3] cycloaddition of benzene at position 3 of the 1,2,4-triazine and the nitrogen atom of the pyridine substituent to afford two spiro-compounds (**I** and **II**). It is obvious that both these intermediates are extremely unstable due to steric hindrance. As a result, cleavage of the N3–C4 bond occurs to form intermediate **III**. Finally, due to the presence of positive and negative charges on the nitrogen atoms, a new N–N bond is generated and the final product **3** is formed.

The mechanism suggests that in order to govern the transformation of the 1,2,4-triazine into a 1,2,3-triazole ring it is necessary to introduce a 2-pyridyl substituent at position 3 of the 1,2,4-triazine ring. To confirm this, we carried out the reaction between 3,5,6-tri-



Scheme 2. A plausible mechanism for the benzene-mediated rearrangement of 3-(2-pyridyl)-1,2,4-triazines into 10-(1*H*-1,2,3-triazol-1-yl)pyrido[1,2-*a*]indoles.



Scheme 3. The formation of 1,3,4-triphenylisoquinoline. Reagents and conditions: (i) toluene, isoamyl nitrite, 110 °C, 1.5 h.

phenyl-1,2,4-triazine (**4**)¹⁴ (an aryl-containing analog of compound **1a**) and benzene (Scheme 2), under the same conditions.

The only product observed in this reaction was triphenylisoquinoline **5**, and no 1,2,3-triazole was isolated. All the spectral data obtained for this compound were in agreement with those reported previously.¹⁵ Thus, the presence of a 2-pyridyl substituent at position 3 of the 1,2,4-triazine is necessary for the transformation of the 1,2,4-triazine into a 1,2,3-triazole (Scheme 3).

In summary, a non-trivial method for the synthesis of 10-(1*H*-1,2,3-triazol-1-yl)pyrido[1,2-*a*]indoles **3** has been reported. Pyrido[1,2-*a*]indoles are important in terms of their biological activity, in particular, cytostatic,¹⁶ antiviral,¹⁷ antitumor,¹⁸ etc. The preparation of these compounds by other synthetic approaches,¹⁹ including reactions with arynes,²⁰ is still rare. A plausible mechanism for this transformation has been suggested, and the necessity for a 2-pyridyl substituent at position 3 of the 1,2,4-triazine ring was confirmed.

Acknowledgments

This work was supported by the Russian Ministry of Education (State Contracts Nos. 14.740.11.1020 and 14.A18.21.0817), RFBR (Grant No. 12-03-31726) and the Council for grants of the President of Russian Federation (Grant No. MK-1511.2013.3).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tetlet.2013.09.042>.

References and notes

1. (a) Kovalev, I. S.; Kopchuk, D. S.; Zyryanov, G. V.; Slepukhin, P. A.; Rusinov, V. L.; Chupakhin, O. N. *Chem. Heterocycl. Compd.* **2012**, *48*, 536; (b) Dubrovskiy, A. V.; Markina, N. A.; Larock, R. C. *Org. Biomol. Chem.* **2013**, *11*, 191.
2. Tadross, P. M.; Stoltz, B. M. *Chem. Rev.* **2012**, *112*, 3550.
3. Gampe, C. M.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2012**, *51*, 3766.
4. (a) Zyryanov, G. V.; Palacios, M. A.; Anzenbacher, P., Jr. *Org. Lett.* **2008**, *10*, 3681; (b) Anzenbacher, P., Jr.; Mosca, L.; Palacios, M. A.; Zyryanov, G. V.; Koutnik, P. *Chem. Eur. J.* **2012**, *18*, 12712.
5. (a) Foster, R. A. A.; Willis, M. C. *Chem. Soc. Rev.* **2013**, *42*, 63; (b) Boger, D. L. *Chem. Rev.* **1986**, *86*, 781.
6. (a) d'A Rocha Gonsalves, A. M.; Melo, T. M. V. D.; Melo, T. M. V. D. P.; Gilchrist, T. L. *Tetrahedron* **1992**, *48*, 6821; (b) Dhar, R.; Huhnermann, W.; Kampchen, T.; Overheu, W.; Seitz, G. *Chem. Ber.* **1983**, *116*, 97.
7. (a) Sasse, W. H. F. *Org. Synth.* **1973**, *5*, 102; (b) Reedijk, J. In *Comprehensive Coordination Chemistry*; Pergamon: Oxford, 1987; Vol. 2, p. 73; (c) Kaes, C.; Katz, A.; Hosseini, M. W. *Chem. Rev.* **2000**, *100*, 3553.
8. Kopchuk, D. S.; Zyryanov, G. V.; Kovalev, I. S.; Egorov, I. N.; Rusinov, V. L.; Chupakhin, O. N. *Chem. Heterocycl. Compd.* **2013**, *48*, 1871.
9. Diring, S.; Retailleau, P.; Ziessel, R. *Tetrahedron Lett.* **2007**, *48*, 8069.
10. Kopchuk, D. S.; Kovalev, I. S.; Khasanov, A. F.; Zyryanov, G. V.; Slepukhin, P. A.; Rusinov, V. L.; Chupakhin, O. N. *Mendeleev Commun.* **2013**, *23*, 142.
11. (a) Case, F. H. *J. Org. Chem.* **1965**, *30*, 931; (b) Kozhevnikov, V. N.; Kozhevnikov, D. N.; Shabunina, O. V.; Rusinov, V. L.; Chupakhin, O. N. *Tetrahedron Lett.* **2005**, *46*, 1791; (c) Kopchuk, D. S.; Zyryanov, G. V.; Kovalev, I. S.; Khasanov, A. F.; Medvedevskikh, A. S.; Rusinov, V. L.; Chupakhin, O. N. *Chem. Heterocycl. Compd.* **2013**, *49*, 500.
12. Huisgen, R.; Knorr, R. *Tetrahedron Lett.* **1963**, *4*, 1017.
13. Crystal data for **3c**: monoclinic, space group $P2_1/c$, $a = 12.4671(15)$, $b = 8.6868(7)$, $c = 17.444(2)$, $\beta = 100.335(11)$ at $295(2)$ K with $Z = 4$, $R_1 = 0.0401$, $GOF = 1.007$. Crystallographic data for structure **3c** have been deposited at the Cambridge Crystallographic Data Centre (CCDC 947859). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +40 (0) 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk].
14. Rostamizadeh, S.; Sadeghi, K. *Synth. Commun.* **2002**, *32*, 1899.
15. Alonso, R.; Campos, P. J.; Garcia, B.; Rodriguez, M. A. *Org. Lett.* **2006**, *8*, 3521.
16. (a) Ambros, R.; Von Angerer, S.; Wiegrefe, W. *Arch. Pharm.* **1988**, *321*, 481; (b) Ambros, R.; Schneider, M. R.; Von Angerer, S. *J. Med. Chem.* **1990**, *33*, 153.
17. Hudyma, T. W.; Zheng, X.; He, F.; Ding, M.; Bergstrom, C. P.; Hewawasam, P.; Martin, S. W.; Gentles, R. G. US Pat. Appl. Publ. 2006, 318, Cont.-In-Part of US Ser. No. 181, 639; *Chem. Abstr.* **2006**, *145*, 189063.
18. Orlemans, E. O. M.; Verboom, W.; Scheltinga, M. W.; Reinhoudt, D. N.; Lelieveld, P.; Fiebig, H. H.; Winterhalter, B. R.; Doublell, J. A.; Bibbyll, M. C. *J. Med. Chem.* **1989**, *32*, 1612.
19. (a) von Braun, N. *Chem. Ber.* **1937**, *70*, 1760; (b) Deegan, A.; Rose, F. L. *J. Org. Chem.* **1971**, *27*, 256; (c) Naredla, R. R.; Zheng, C.; Nilsson Lill, S. O.; Klumpp, D. A. *J. Am. Chem. Soc.* **2011**, *133*, 13169; (d) Soldatenkov, A. T.; Bagdadi, M. V.; Formichev, A. A.; Prostakov, N. S. *J. Org. Chem. USSR* **1982**, *18*, 783; (e) Ohsawa, A.; Kawaguchi, T.; Igeta, H. *Chem. Lett.* **1981**, *1737*; (f) Gaster, L. M.; Wyman P. A. US Patent 005,998,409A, 1995; *Chem. Abstr.* **1995**, *122*, 265390.
20. Rogness, D. C.; Markina, N. A.; Waldo, J. P.; Larock, R. C. *J. Org. Chem.* **2012**, *77*, 2743.